Mitochondrial ion channels as oncological targets

Oncogene

Volumn 33, Issue 49, 2014, Pages 5569-5581

  Leanza, L ^a   Zoratti, M ^a   Gulbins, E ^b   Szabo, I ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

direct targeting; ion channels; mitochondria; pharmacology

Indexed keywords

CALCIUM; ION CHANNEL; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL UNCOUPLING PROTEIN; PORIN; POTASSIUM CHANNEL; REACTIVE OXYGEN METABOLITE;

ANIMAL; APOPTOSIS; CELL DEATH; HOMEOSTASIS; HUMAN; METABOLISM; MITOCHONDRION; MOUSE; NEOPLASMS; PERMEABILITY;

ANIMALS; APOPTOSIS; CALCIUM; CELL DEATH; HOMEOSTASIS; HUMANS; ION CHANNELS; MICE; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NEOPLASMS; PERMEABILITY; PORINS; POTASSIUM CHANNELS; REACTIVE OXYGEN SPECIES;

EID: 84925224409     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.578     Document Type: Review

References (194)

1. Galluzzi L, Kepp O, Kroemer G. Mitochondria: Master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13: 780-788.
2. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010; 9: 447-464.
3. Bender T, Martinou JC. Where killers meet-permeabilization of the outer mitochondrial membrane during apoptosis. Cold Spring Harb Perspect Biol 2013; 5: A011106.
4. Dejean LM, Ryu SY, Martinez-Caballero S, Teijido O, Peixoto PM, KW Kinnally. MAC and Bcl-2 family proteins conspire in a deadly plot. Biochim Biophys Acta 2010; 1797: 1231-1238.
5. Starkov AA. The role of mitochondria in reactive oxygen species metabolism and signaling. Ann NY Acad Sci 2008; 1147: 37-52.
6. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009; 417: 1-13.
7. Kadenbach B. Intrinsic and extrinsic uncoupling of oxidative phosphorylation. Biochim Biophys Acta 2003; 1604: 77-94.
8. Malinska D, Mirandola SR, Kunz WS. Mitochondrial potassium channels and reactive oxygen species. FEBS Lett 2010; 584: 2043-2048.
9. Kowaltowski AJ, De Souza-Pinto NC, Castilho RF, Vercesi AE. Mitochondria and reactive oxygen species. Free Radic Biol Med 2009; 47: 333-343.
10. Demin OV, Kholodenko BN, Skulachev VP. A model of O2.-generation in the complex III of the electron transport chain. Mol Cell Biochem 1998; 184: 21-33.
11. O-Uchi J, Ryu SY, Jhun BS, Hurst S, Sheu SS. Mitochondrial ion channels/transporters as sensors and regulators of cellular redox signaling. Antioxid Redox Signal 2013; PMID: 24180309.
12. Orr AL, Quinlan CL, Perevoshchikova IV, Brand MD. A refined analysis of superoxide production by mitochondrial sn-glycerol 3-phosphate dehydrogenase. J Biol Chem 2012; 287: 42921-42935.
13. Quinlan CL, Perevoshchikova IV, Hey-Mogensen M, Orr AL, Brand MD. Sites of reactive oxygen species generation by mitochondria oxidizing different substrates. Redox Biol 2013; 1: 304-312.
14. Fiaschi T, Chiarugi P. Oxidative stress, tumor microenvironment, and metabolic reprogramming: A diabolic liaison. Int J Cell Biol 2012; 2012: 762825.
15. Biasutto L, Szabo I, Zoratti M. Mitochondrial effects of plant-made compounds. Antioxid Redox Signal 2012; 15: 3039-3059.
16. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011; 334: 1278-1283.
17. Ueda S, Masutani H, Nakamura H, Tanaka T, Ueno M, Yodoi J. Redox control of cell death. Antioxid Redox Signal 2002; 4: 405-414.
18. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 2010; 48: 749-762.
19. Panieri E, Gogvadze V, Norberg E, Venkatesh R, Orrenius S, Zhivotovsky B. Reactive oxygen species generated in different compartments induce cell death, survival, or senescence. Free Radic Biol Med 2013; 57: 176-187.
20. Bialik S, Kimchi A. The death-associated protein kinases: Structure, function, and beyond. Annu Rev Biochem 2006; 75: 189-210.
21. Takeda K, Noguchi T, Naguro I, Ichijo H. Apoptosis signal-regulating kinase 1 in stress and immune response. Annu Rev Pharmacol Toxicol 2008; 48: 199-225.
22. Ghibelli L, Diederich M. Multistep and multitask Bax activation. Mitochondrion 2010; 10: 604-613.
23. Scorrano L. Opening the doors to cytochrome c: Changes in mitochondrial shape and apoptosis. Int J Biochem Cell Biol 2009; 41: 1875-1883.
24. Landes T, Martinou JC. Mitochondrial outer membrane permeabilization during apoptosis: The role of mitochondrial fission. Biochim Biophys Acta 2011; 1813: 540-545.
25. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-591.
26. Ralph SJ, Rodr?guez-Enr?quez S, Neuzil J, Saavedra E, Moreno-Sánchez R. The causes of cancer revisited: ?mitochondrial malignancy' and ROS-induced oncogenic transformation-why mitochondria are targets for cancer therapy. Mol Aspects Med 2010; 31: 145-170.
27. Ralph SJ, Moreno-Sánchez R, Neuzil J, Rodr?guez-Enr?quez S. Inhibitors of succinate: Quinone reductase/Complex II regulate production of mitochondrial reactive oxygen species and protect normal cells from ischemic damage but induce specific cancer cell death. Pharm Res 2011; 28: 2695-2730.
28. Wang J, Yi J. Cancer cell killing via ROS: To increase or decrease, that is the question. Cancer Biol Ther 2008; 7: 1875-1884.
29. Kirichok Y, Krapivinsky G, Clapham DE. The mitochondrial calcium uniporter is a highly selective ion channel. Nature 2004; 427: 360-364.
30. Gunter TE, Buntinas L, Sparagna G, Eliseev R, Gunter K. Mitochondrial calcium transport: Mechanisms and functions. Cell Calcium 2000; 28: 285-296.
31. Drago I, Pizzo P, Pozzan T. After half a century mitochondrial calcium in-and efflux machineries reveal themselves. EMBO J 2011; 30: 4119-4125.
32. Kinnally KW, Peixoto PM, Ryu SY, Dejean LM. Is mMPTP the gatekeeper for necrosis, apoptosis, or both? Biochim Biophys Acta 2011; 1813: 616-622.
33. Rasola A, Bernardi P. Mitochondrial permeability transition in Ca(2)-dependent apoptosis and necrosis. Cell Calcium 2011; 50: 222-233.
34. Peng TI, Jou MJ. Oxidative stress caused by mitochondrial calcium overload. Ann NY Acad Sci 2010; 1201: 183-188.
35. Maack C, Cortassa S, Aon MA, Ganesan AN, Liu T, O'Rourke B. Elevated cytosolic Na decreases mitochondrial Ca2 uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes. Circ Res 2006; 99: 172-182.
36. Nichols BJ, Denton RM. Towards the molecular basis for the regulation of mitochondrial dehydrogenases by calcium ions. Mol Cell Biochem 1995; 149-150: 203-212.
37. Denton RM. Regulation of mitochondrial dehydrogenases by calcium ions. Biochim Biophys Acta 2009; 1787: 1309-1316.
38. Pedersen PL. The cancer cell's ?power plants' as promising therapeutic targets: An overview. J Bioenerg Biomembr 2007; 39: 1-12.
39. Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012; 12: 685-698.
40. Halestrap AP. The regulation of the oxidation of fatty acids and other substrates in rat heart mitochondria by changes in the matrix volume induced by osmotic strength, valinomycin and Ca2. Biochem J 1987; 244: 159-164.
41. Aon MA, Cortassa S, Wei AC, Grunnet M, O'Rourke B. Energetic performance is improved by specific activation of K fluxes through K(Ca) channels in heart mitochondria. Biochim Biophys Acta 2010; 1797: 71-80.
42. Venediktova N, Shigaeva M, Belova S, Belosludtsev K, Belosludtseva N, Gorbacheva O, Lezhnev E, Lukyanova L, Mironova G. Oxidative phosphorylation and ion transport in the mitochondria of two strains of rats varying in their resistance to stress and hypoxia. Mol Cell Biochem 2013; 383: 261-269.
43. Bednarczyk P, Wieckowski MR, Broszkiewicz M, Skowronek K, Siemen D, Szewczyk A. Putative structural and functional coupling of the mitochondrial BKCa channel to the respiratory chain. PLoS One 2013; 8: E68125.
44. Cogliati S, Frezza C, Soriano ME, Varanita T, Quintana-Cabrera R, Corrado M et al. Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency. Cell 2013; 155: 160-171.
45. Perevoshchikova IV, Zorov SD, Kotova EA, Zorov DB, Antonenko YN. Hexokinase inhibits flux of fluorescently labeled ATP through mitochondrial outer membrane porin. FEBS Lett 2010; 584: 2397-2402.
46. Lemasters JJ, Holmuhamedov E. Voltage-dependent anion channel (VDAC) as mitochondrial governator-thinking outside the box. Biochim Biophys Acta 2006; 1762: 181-190.
47. Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V. In self-defence: Hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J 2004; 377: 347-355.
48. Shoshan-Barmatz V, De Pinto V, Zweckstetter M, Raviv Z, Keinan N, Arbel N. VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol Aspects Med 2010; 31: 227-285.
49. Zoratti M, De Marchi U, Gulbins E, Szabò I. Novel channels of the inner mitochondrial membrane. Biochim Biophys Acta 2009; 1787: 351-363.
50. Szabò I, Leanza L, Gulbins E, Zoratti M. Physiology of potassium channels in the inner membrane of mitochondria. Pflugers Arch 2012; 463: 231-246.
51. Rizzuto R, De Stefani D, Raffaello A, Mammucari C. Mitochondria as sensors and regulators of calcium signalling. Nat Rev Mol Cell Biol 2012; 13: 566-578.
52. Tan W. VDAC blockage by phosphorothioate oligonucleotides and its implication in apoptosis. Biochim Biophys Acta 2012; 1818: 1555-1561.
53. Grills C, Jithesh PV, Blayney J, Zhang SD, Fennell DA. Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer. PLoS One 2011; 6: E14635.
54. McCommis KS, Baines CP. The role of VDAC in cell death: Friend or foe? Biochim Biophys Acta, 2012; 1818: 1444-1450.
55. Shoshan-Barmatz V, Golan M. Mitochondrial VDAC1: Function in cell life and death and a target for cancer therapy. Curr Med Chem 2012; 19: 714-735.
56. Shoshan-Barmatz V, Mizrachi D. VDAC1: From structure to cancer therapy. Front Oncol 2012; 2: 164.
57. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 2011; 208: 313-326.
58. Koren I, Raviv Z, Shoshan-Barmatz V. Downregulation of voltage-dependent anion channel-1 expression by RNA interference prevents cancer cell growth in vivo. Cancer Biol Ther 2010; 9: 1046-1052.
59. Zaid H, Abu-Hamad S, Israelson A, Nathan I, Shoshan-Barmatz V. The voltagedependent anion channel-1 modulates apoptotic cell death. Cell Death Differ 2005; 12: 751-760.
60. Mader A, Abu-Hamad S, Arbel N, Gutié rrez-Aguilar M, Shoshan-Barmatz V. Dominant-negative VDAC1 mutants reveal oligomeric VDAC1 to be the active unit in mitochondria-mediated apoptosis. Biochem J 2010; 429: 147-155.
61. Sharaf el dein O, Gallerne C, Brenner C, Lemaire C. Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by DNA cross-linking agents. Biochem Pharmacol 2012; 83: 1172-1182.
62. Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 2002; 277: 7610-7618.
63. Gall JM, Wong V, Pimental DR, Havasi A, Wang Z, Pastorino JG et al. Hexokinase regulates Bax-mediated mitochondrial membrane injury following ischemic stress. Kidney Int 2011; 79: 1207-1216.
64. Chiara F, Castellaro D, Marin O, Petronilli V, Brusilow WS, Juhaszova M et al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS One 2008; 3: E1852.
65. Fingrut O, Flescher E. Plant stress hormones suppress the proliferation and induce apoptosis in human cancer cells. Leukemia 2002; 16: 608-616.
66. Klippel S, Jakubikova J, Delmore J, Ooi M, McMillin D, Kastritis E et al. Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. Br J Haematol 2012; 159: 340-351.
67. Palmieri B, Iannitti T, Capone S, Flescher E. A preliminary study of the local treatment of preneoplastic and malignant skin lesions using methyl jasmonate. Eur Rev Med Pharmacol Sci 2011; 15: 333-336.
68. Kim JH, Lee SY, Oh SY, Han SI, Park HG, Yoo MA et al. Methyl jasmonate induces apoptosis through induction of Bax/Bcl-XS and activation of caspase-3 via ROS production in A549 cells. Oncol Rep 2004; 12: 1233-1238.
69. Tong QS, Jiang GS, Zheng LD, Tang ST, Cai JB, Liu Y et al. Methyl jasmonate downregulates expression of proliferating cell nuclear antigen and induces apoptosis in human neuroblastoma cell lines. Anticancer Drugs 2008; 19: 573-581.
70. Davies NJ, Hayden RE, Simpson PJ, Birtwistle J, Mayer K, Ride JP et al. AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects. Cancer Res 2009; 69: 4769-4775.
71. Ji Q, Chang L, VanDenBerg D, Stanczyk FZ, Stolz A. Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. Prostate 2003; 54: 275-289.
72. Vihko P, Herrala A, Härkönen P, Isomaa V, Kaija H, Kurkela R et al. Enzymes as modulators in malignant transformation. J Steroid Biochem Mol Biol 2005; 93: 277-283.
73. De Marchi U, Sassi N, Fioretti B, Catacuzzeno L, Cereghetti GM, Szabò I et al. Intermediate conductance Ca2-activated potassium channel (KCa3.1) in the inner mitochondrial membrane of human colon cancer cells. Cell Calcium 2009; 45: 509-516.
74. Quast SA, Berger A, Buttstädt N, Friebel K, Schö nherr R, Eberle J. General sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMAC. PLoS One 2012; 7: E39290.
75. Gelb BD, Adams V, Jones SN, Griffin LD, MacGregor GR, McCabe ER. Targeting of hexokinase 1 to liver and hepatoma mitochondria. Proc Natl Acad Sci USA 1992; 89: 202-206.
76. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K et al. Hexokinasemitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 2004; 16: 819-830.
77. Pedersen PL. 3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective ?small molecule' anti-cancer agent taken from labside to bedside: Introduction to a special issue. J Bioenerg Biomembr 2012; 44: 1-6.
78. Shoshan MC. 3-Bromopyruvate: Targets and outcomes. J Bioenerg Biomembr 2012; 44: 7-15.
79. Ko YH, Verhoeven HA, Lee MJ, Corbin DJ, Vogl TJ, Pedersen PL. A translational study case report on the small molecule energy blocker 3-bromopyruvate (3BP) as a potent anticancer agent: From bench side to bedside. J Bioenerg Biomembr 2012; 44: 163-170.
80. Cardaci S, Desideri E, Ciriolo MR. Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug. J Bioenerg Biomembr 2012; 44: 17-29.
81. Galluzzi L, Kepp O, Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat Rev Drug Discov 2013; 12: 829-846.
82. Tang Z, Yuan S, Hu Y, Zhang H, Wu W, Zeng Z et al. Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester. J Bioenerg Biomembr 2012; 44: 117-125.
83. Rodrigues-Ferreira C, da Silva AP, Galina A. Effect of the antitumoral alkylating agent 3-bromopyruvate on mitochondrial respiration: Role of mitochondrially bound hexokinase. J Bioenerg Biomembr 2012; 44: 39-49.
84. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS et al. Advanced cancers: Eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004; 324: 269-275.
85. Lau E, Kluger H, Varsano T, Lee KY, Scheffler I, Rimm DL et al. PKCE promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell 2012; 148: 543-555.
86. Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS, Fridman DJ et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 2007; 447: 864-868.
87. Tikunov A, Johnson CB, Pediaditakis P, Markevich N, Macdonald JM, Lemasters JJ et al. Closure of VDAC causes oxidative stress and accelerates the Ca(2)-induced mitochondrial permeability transition in rat liver mitochondria. Arch Biochem Biophys 2010; 495: 174-181.
88. Simamura E, Shimada H, Hatta T, Hirai K. Mitochondrial voltage-dependent anion channels (VDACs) as novel pharmacological targets for anti-cancer agents. J Bioenerg Biomembr 2008; 40: 213-217.
89. Tsujimoto Y, Shimizu S. VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ 2000; 7: 1174-1181.
90. Martinez-Caballero S, Dejean LM, Kinnally MS, Oh KJ, Mannella CA, Kinnally KW. Assembly of the mitochondrial apoptosis-induced channel, MAC. J Biol Chem 2009; 284: 12235-12245.
91. Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008; 27: 4221-4232.
92. Tomasello F, Messina A, Lartigue L, Schembri L, Medina C, Reina S et al. Outer membrane VDAC1 controls permeability transition of the inner mitochondrial membrane in cellulo during stress-induced apoptosis. Cell Res 2009; 19: 1363-1376.
93. Baines CP, Kaiser RA, Sheik T, Craigen WJ, Molkentin JD. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol 2007; 9: 550-555.
94. Shimizu S, Ide T, Yanagida T, Tsujimoto Y. Electrophysiological study of a novel large pore formed by Bax and the voltage-dependent anion channel that is permeable to cytochrome c. J Biol Chem 2000; 275: 12321-12325.
95. Arbel N, Ben-Hail D, Shoshan-Barmatz V. Mediation of the antiapoptotic activity of Bcl-xL protein upon interaction with VDAC1 protein. J Biol Chem 2012; 287: 23152-23161.
96. Prezma T, Shteinfer A, Admoni L, Raviv Z, Sela I, Levi I, Shoshan-Barmatz V. VDAC1-based peptides: Novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia. Cell Death Dis 2013; 4: E809.
97. Brenner C, Grimm S. The permeability transition pore complex in cancer cell death. Oncogene 2006; 25: 4744-4756.
98. Bernardi P. The mitochondrial permeability transition pore: A mystery solved? Front Physiol 2013; 4: 95.
99. Szabó I, Zoratti M. The giant channel of the inner mitochondrial membrane is inhibited by cyclosporin A. J Biol Chem 1991; 266: 3376-3379.
100. Giorgio V, von Stockum S, Antoniel M, Fabbro A, Fogolari F, Forte M et al. Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc Natl Acad Sci USA 2013; 110: 5887-5892.
101. Rasola A, Sciacovelli M, Pantic B, Bernard P. Signal transduction to the permeability transition pore. FEBS Lett 2010; 584: 1989-1896.
102. Traba J, Del Arco A, Duchen MR, Szabadkai G, Satrú stegui J. SCaMC-1 promotes cancer cell survival by desensitizing mitochondrial permeability transition via ATP/ADP-mediated matrix Ca(2) buffering. Cell Death Differ 2012; 19: 650-660.
103. Matassa DS, Amoroso MR, Maddalena F, Landriscina M, Esposito F. New insights into TRAP1 pathway. Am J Cancer Res 2012; 2: 235-248.
104. Chiara F, Gambalunga A, Sciacovelli M, Nicolli A, Ronconi L, Fregona D et al. Chemotherapeutic induction of mitochondrial oxidative stress activates GSK-3a/b and Bax, leading to permeability transition pore opening and tumor cell death. Cell Death Dis 2012; 3: E444.
105. Elliott MA, Ford SJ, Prasad E, Dick LJ, Farmer H, Hogg PJ et al. Pharmaceutical development of the novel arsenical based cancer therapeutic GSAO for Phase I clinical trial. Int J Pharm 2012; 426: 67-75.
106. Brenner C, Moulin M. Physiological roles of the permeability transition pore. Circ Res 2012; 111: 1237-1247.
107. Jones S, Martel C, Belzacq-Casagrande AS, Brenner C, Howl J. Mitoparan and target-selective chimeric analogues: Membrane translocation and intracellular redistribution induces mitochondrial apoptosis. Biochim Biophys Acta 2008; 1783: 849-863.
108. Risso A, Braidot E, Sordano MC, Vianello A, Macr? F, Skerlavaj B et al. BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Mol Cell Biol 2002; 22: 1926-1935.
109. Horton KL, Pereira MP, Stewart KM, Fonseca SB, Kelley SO. Tuning the activity of mitochondria-penetrating peptides for delivery or disruption. Chembiochem 2012; 13: 476-485.
110. Rasola A, Sciacovelli M, Chiara F, Pantic B, Brusilow WS, Bernardi P. Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc Natl Acad Sci USA 2010; 107: 726-731.
111. Chiara F, Rasola A. GSK-3 and mitochondria in cancer cells. Front Oncol 2013; 3: 16.
112. Flescher E. Jasmonates-a new family of anti-cancer agents. Anticancer Drugs 2005; 16: 911-916.
113. Flescher E. Jasmonates in cancer therapy. Cancer Lett 2007; 245: 1-10.
114. Raviv Z, Cohen S, Reischer-Pelech D. The anti-cancer activities of jasmonates. Cancer Chemother Pharmacol 2013; 71: 275-285.
115. Lena A, Rechichi M, Salvetti A, Bartoli B, Vecchio D, Scarcelli V et al. Drugs targeting the mitochondrial pore act as cytotoxic and cytostatic agents in temozolomide-resistant glioma cells. J Transl Med 2009; 7: 13.
116. Javadov S, Hunter JC, Barreto-Torres G, Parodi-Rullan R. Targeting the mitochondrial permeability transition: Cardiac ischemia-reperfusion versus carcinogenesis. Cell Physiol Biochem 2011; 27: 179-190.
117. Pereira GC, Branco AF, Matos JA, Pereira SL, Parke D, Perkins EL et al. Mitochondrially targeted effects of berberine [Natural Yellow 18, 5,6-dihydro-9,10-dimethoxybenzo(g)-1,3-benzodioxolo(5,6-a) quinolizinium] on K1735-M2 mouse melanoma cells: Comparison with direct effects on isolated mitochondrial fractions. J Pharmacol Exp Ther 2007; 323: 636-649.
118. Pereira CV, Machado NG, Oliveira PJ. Mechanisms of berberine (natural yellow 18)-induced mitochondrial dysfunction: Interaction with the adenine nucleotide translocator. Toxicol Sci 2008; 105: 408-417.
119. Li L, Han W, Gu Y, Qiu S, Lu Q, Jin J et al. Honokiol induces a necrotic cell death through the mitochondrial permeability transition pore. Cancer Res 2007; 67: 4894-4903.
120. Dong JX, Zhao GY, Yu QL, Li R, Yuan L, Chen J et al. Mitochondrial dysfunction induced by honokiol. J Membr Biol 2013; 246: 375-381.
121. Cavalieri E, Bergamini C, Mariotto S, Leoni S, Perbellini L, Darra E et al. Involvement of mitochondrial permeability transition pore opening in alpha-bisabolol induced apoptosis. FEBS J 2009; 276: 3990-4000.
122. Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y et al. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 2007; 6: 1641-1649.
123. Broekemeier KM, Dempsey ME, Pfeiffer DR. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J Biol Chem 1989; 264: 7826-7830.
124. Crompton M, Ellinger H, Costi A. Inhibition by cyclosporin A of a Ca2-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress. Biochem. J 1988; 255: 357-360.
125. Fournier N, Ducet G, Crevat A. Action of cyclosporine on mitochondrial calcium fluxes. J Bioenerg Biomembr 1987; 19: 297-303.
126. Norman KG, Canter JA, Shi M, Milne GL, Morrow JD, Sligh JE. Cyclosporine A suppresses keratinocyte cell death through MMPTP inhibition in a model for skin cancer in organ transplant recipients. Mitochondrion 2010; 10: 94-101.
127. Szabò I, Bock J, Jekle A, Soddemann M, Adams C, Lang F et al. A novel potassium channel in lymphocyte mitochondria. J Biol Chem 2005; 280: 12790-12798.
128. Gulbins E, Sassi N, Grassmè H, Zoratti M, Szabò I. Role of Kv1.3 mitochondrial potassium channel in apoptotic signalling in lymphocytes. Biochim Biophys Acta 2010; 1797: 1251-1259.
129. Szabó I, Bock J, Grassmé H, Soddemann M, Wilker B, Lang F et al. Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes. Proc Natl Acad Sci USA 2008; 105: 14861-14866.
130. Szabò I, Soddemann M, Leanza L, Zoratti M, Gulbins E. Single-point mutations of a lysine residue change function of Bax and Bcl-xL expressed in Bax-and Bakless mouse embryonic fibroblasts: Novel insights into the molecular mechanisms of Bax-induced apoptosis. Cell Death Differ 2011; 18: 427-438.
131. Annis MG, Soucie EL, Dlugosz PJ, Cruz-Aguado JA, Penn LZ, Leber B et al. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J 24: 2096-2103.
132. Leanza L, Zoratti M, Gulbins E, Szabò I. Induction of apoptosis in macrophages via Kv1.3 and Kv1.5 potassium channels. Curr Med Chem 2012; 19: 5394-5404.
133. Leanza L, Henry B, Sassi N, Zoratti M, Chandy KG, Gulbins E et al. Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells. EMBO Mol Med 2012; 4: 577-593.
134. Leanza L, Trentin L, Becker KA, Frezzato F, Zoratti M, Semenzato G et al. Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia. Leukemia 2013; 27: 1782-1785.
135. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 2009; 8: 579-591.
136. Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W et al. Inhibition of mitochondrial respiration: A novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 2003; 278: 37832-37839.
137. Ren YR, Pan F, Parvez S, Fleig A, Chong CR, Xu J et al. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One 2008; 3: E4009.
138. Felipe A, Bielanska J, Comes N, Vallejo A, Roig S, Ramón Y, Cajal S et al. Targeting the voltage-dependent K() channels Kv1.3 and Kv1.5 as tumor biomarkers for cancer detection and prevention. Curr Med Chem 2012; 19: 661-674.
139. Leanza L, O' Reilly P, Doyle A, Venturini E, Zoratti M, Szegezdi E et al. Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines. Curr Pharm Des 2013; PMID:23701546.
140. Liu J, Mu C, Yue W, Li J, Ma B, Zhao L et al. A diterpenoid derivate compound targets selenocysteine of Thioredoxin Reductases and induces Bax/Bak-independent apoptosis. Free Radic Biol Med 2013; 63: 485-494.
141. Ni B, Ma Q, Li B, Zhao L, Liu Y, Zhu Y, Chen Q. Phenylarsine oxide induces apoptosis in Bax-and Bak-deficient cells through upregulation of Bim. Clin Cancer Res 2012; 18: 140-145.
142. Lei X, Chen Y, Du G, Yu W, Wang X, Qu H et al. Gossypol induces Bax/Bakindependent activation of apoptosis and cytochrome c release via a conformational change in Bcl-2. FASEB J 2006; 20: 2147-2149.
143. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8: 274-281.
144. McCurrach ME, Connor TM, Knudson CM, Korsmeyer SJ, Lowe SW. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 1997; 94: 2345-2349.
145. Meijerink JP, Mensink EJ, Wang K, Sedlak TW, Slö etjes AW, De Witte T et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 1998; 91: 2991-2997.
146. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 2000; 97: 10872-10877.
147. Sassi N, De Marchi U, Fioretti B, Biasutto L, Gulbins E, Francolini F et al. An investigation of the occurrence and properties of the mitochondrial intermediate conductance Ca2-activated K channel mtKCa3.1. Biochim Biophys Acta Bioenergetics 2010; 1797: 1260-1267.
148. Stowe DF, Gadicherla AK, Zhou Y, Aldakkak M, Cheng Q, Kwok WM et al. Protection against cardiac injury by small Ca(2)-sensitive K() channels identified in guinea pig cardiac inner mitochondrial membrane. Biochim Biophys Acta 2013; 1828: 427-442 2013.
149. Dolga AM, Netter MF, Perocchi F, Doti N, Meissner L, Tobaben S et al. Mitochondrial small conductance SK2 channels prevent glutamate-induced oxytosis and mitochondrial dysfunction. J Biol Chem 2013; 288: 10792-10804.
150. Singh H, Stefani E, Toro L. Intracellular BK(Ca) (iBK(Ca)) channels. J Physiol 2012; 23: 5937-5947.
151. Debska-Vielhaber G, Godlewski MM, Kicinska A, Skalska J, Kulawiak B, Piwonska M, Zablocki K, Kunz WS, Szewczyk A, Motyl T. Large-conductance K channel openers induce death of human glioma cells. J Physiol Pharmacol 2009; 60: 27-36.
152. Wrzosek A, Tomaskova Z, Ondrias K, Lukasiak A, Szewczyk A. The potassium channel opener CGS7184 activates Ca2 release from the endoplasmic reticulum. Eur J Pharmacol 2012; 690: 60-67.
153. Rusznák Z, Bakondi G, Kosztka L, Pocsai K, Dienes B, Fodor J et al. Mitochondrial expression of the two-pore domain TASK-3 channels in malignantly transformed and non-malignant human cells. Virchows Arch 2008; 452: 415-426.
154. Kovács I, Pocsai K, Czifra G, Sarkadi L, Szü cs G, Nemes Z et al. TASK-3 immunoreactivity is present but shows differential distribution in the human gastrointestinal tract. Virchows Arch 2005; 446: 402-410.
155. Kosztka L, Rusznák Z, Nagy D, Nagy Z, Fodor J, Szucs G et al. Inhibition of TASK-3 (KCNK9) channel biosynthesis changes cell morphology and decreases both DNA content and mitochondrial function of melanoma cells maintained in cell culture. Melanoma Res 2011; 21: 308-322.
156. Toczy"owska-Mamiń ska R, Olszewska A, Laskowski M, Bednarczyk P, Skowronek K, Szewczyk A. Potassium Channel in the Mitochondria of Human Keratinocytes. J Invest Dermatol 2013; doi:10.1038/jid.2013.422.
157. Lee GW, Park HS, Kim EJ, Cho YW, Kim GT, Mun YJ et al. Reduction of breast cancer cell migration via up-regulation of TASK-3 two-pore domain K channel. Acta Physiol 2012; 204: 513-524.
158. Innamaa A, Jackson L, Asher V, Van Shalkwyk G, Warren A, Hay D et al. Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma. Anticancer Res 2013; 33: 1401-1408.
159. Fedorenko A, Lishko PV, Kirichok Y. Mechanism of fatty-acid-dependent UCP1 uncoupling in brown fat mitochondria. Cell 2012; 151: 400-413.
160. Hoang T, Smith MD, Jelokhani-Niaraki M. Toward understanding the mechanism of ion transport activity of neuronal uncoupling proteins UCP2, UCP4, and UCP5. Biochemistry 2012; 51: 4004-4014.
161. Cannon B, Nedergaard J. Brown adipose tissue: Function and physiological significance. Physiol Rev 2004; 84: 277-359.
162. Baffy G. Uncoupling protein-2 and cancer. Mitochondrion 2010; 10: 243-252.
163. Baffy G, Derdak Z, Robson SC. Mitochondrial recoupling: A novel therapeutic strategy for cancer? Br J Cancer 2011; 105: 469-474.
164. Cannon B, Shabalina IG, Kramarova TV, Petrovic N, Nedergaard J. Uncoupling proteins: A role in protection against reactive oxygen species-or not? Biochim Biophys Acta 2006; 1757: 449-458.
165. Arsenijevic D, Onuma H, Pecqueur C, Raimbault S, Manning BS, Miroux B et al. Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. Nat Genet 2000; 26: 435-439.
166. Derdak Z, Mark NM, Beldi G, Robson SC, Wands JR, Baffy G. The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res 2008; 68: 2813-2819.
167. Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, Andreeff M. The Warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 2008; 68: 5198-5205.
168. Ayyasamy V, Owens KM, Desouki MM, Liang P, Bakin A, Thangaraj K et al. Cellular model of Warburg effect identifies tumor promoting function of UCP2 in breast cancer and its suppression by genipin. PLoS One 2011; 6: E24792.
169. Sanchez-Alvarez R, Martinez-Outschoorn UE, Lamb R, Hulit J, Howell A, Gandara R et al. Mitochondrial dysfunction in breast cancer cells prevents tumor growth: Understanding chemoprevention with metformin. Cell Cycle 2013; 12: 172-182.
170. De Stefani D, Raffaello A, Teardo E, Szabò I, Rizzuto R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 2011; 476: 336-340.
171. Baughman JM, Perocchi F, Girgis HS, Plovanich M, Belcher-Timme CA, Sancak Y et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature 2011; 476: 341-345.
172. Pinton P, Ferrari D, Rapizzi E, Di Virgilio F, Pozzan T, Rizzuto R. The Ca2 concentration of the endoplasmic reticulum is a key determinant of ceramideinduced apoptosis: Significance for the molecular mechanism of Bcl-2 action. EMBO J 2001; 20: 2690-2701.
173. Mallilankaraman K, Doonan P, Cárdenas C, Chandramoorthy HC, Mü ller M, Miller R et al. MICU1 is an essential gatekeeper for MCU-mediated mitochondrial Ca(2) uptake that regulates cell survival. Cell 2012; 151: 630-644.
174. Raffaello A, De Stefani D, Sabbadin D, Teardo E, Merli G, Picard A et al. The mitochondrial calcium uniporter is a multimer that can include a dominantnegative pore-forming subunit. EMBO J 2013; 32: 2362-2376.
175. Marchi S, Lupini L, Patergnani S, Rimessi A, Missiroli S, Bonora M et al. Downregulation of the Mitochondrial calcium uniporter by cancer-related miR-25. Curr Biol 2013; 23: 58-63.
176. Curry MC, Peters AA, Kenny PA, Roberts-Thomson SJ, Monteith GR. Mitochondrial calcium uniporter silencing potentiates caspase-independent cell death in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 2013; 434: 695-700.
177. Arvizo RR, Moyano DF, Saha S, Thompson MA, Bhattacharya R, Rotello VM et al. Probing novel roles of the mitochondrial uniporter in ovarian cancer cells using nanoparticles. J Biol Chem 2013; 288: 17610-17618.
178. Davis FM, Parsonage MT, Cabot PJ, Parat MO, Thompson EW, Roberts-Thomson SJ et al. Assessment of gene expression of intracellular calcium channels, pumps and exchangers with epidermal growth factor-induced epithelial-mesenchymal transition in a breast cancer cell line. Cancer Cell Int 2013; 13: 76.
179. Pan X, Liu J, Nguyen T, Liu C, Sun J, Teng Y et al. The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. Nat Cell Biol 2013; 15: 1464-1472.
180. Sancak Y, Markhard AL, Kitami T, Kovács-Bogdán E, Kamer KJ, Udeshi ND et al. EMRE is an essential component of the mitochondrial calcium uniporter complex. Science 2013; 342: 1379-1382.
181. Chaudhuri D, Sancak Y, Mootha VK, Clapham DE. MCU encodes the pore conducting mitochondrial calcium currents. Elife 2013; 2: E00704.
182. Plovanich M, Bogorad RL, Sancak Y, Kamer KJ, Strittmatter L, Li AA et al. MICU2, a paralog of MICU1, resides within the mitochondrial uniporter complex to regulate calcium handling. PLoS One 2013; 8: E55785.
183. Wang YZ, Zeng WZ, Xiao X, Huang Y, Song XL, Yu Z et al. Intracellular ASIC1a regulates mitochondrial permeability transition-dependent neuronal death. Cell Death Differ 2013; 20: 1359-1369.
184. Friese MA, Craner MJ, Etzensperger R, Vergo S, Wemmie JA, Welsh MJ et al. Acidsensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med 2007; 13: 1483-1489.
185. Ko JH, Ko EA, Gu W, Lim I, Bang H, Zhou T. Expression profiling of ion channel genes predicts clinical outcome in breast cancer. Mol Cancer 2013; 12: 106.
186. Smith RA, Hartley RC, Murphy MP. Mitochondria-targeted small molecule therapeutics and probes. Antioxid Redox Signal 2011; 15: 3021-3038.
187. Smith RA, Hartley RC, Cochemé HM, Murphy MP. Mitochondrial pharmacology. Trends Pharmacol Sci. 2012; 33: 341-352.
188. Neuzil J, Dong LF, Rohlena J, Truksa J, Ralph SJ. Classification of mitocans, anti-cancer drugs acting on mitochondria. Mitochondrion 2013; 13: 199-208.
189. Galluzzi LMorselli E, Kepp O, Tajeddine N, Kroemer G. Targeting p53 to mitochondria for cancer therapy. Cell Cycle 2008; 7: 1949-1955.
190. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME, Debatin KM. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 1998; 273: 33942-33948.
191. Cavalieri E, Rigo A, Bonifacio M, Carcereri De Prati A, Guardalben E, Bergamini C, Fato R, Pizzolo G, Suzuki H, Vinante F. Pro-apoptotic activity of a-bisabolol in preclinical models of primary human acute leukemia cells. J Transl Med 2011; 9: 45.
192. Guo XP, Zhang XY, Zhang SD. Clinical trial on the effects of shikonin mixture on later stage lung cancer. Zhong Xi Yi Jie He Za Zhi 1991; 11: 598-599.
193. Schonherr R. Clinical relevance of ion channels for diagnosis and therapy of cancer. J Membr Biol 2005; 205: 175-184.
194. Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, Chandy KG. Design of a potent and selective inhibitor of the intermediate-conductance Ca2-activated K channel, IKCa1: A potential immunosuppressant. Proc Natl Acad Sci USA 2000; 97: 8151-8156.